When Investors Want More Than a Return

In May 2026, the Delaware Court of Chancery declined to dismiss claims arising from a corporate investor’s USD2.9 million investment in a startup for a 5% stake, a board seat filled by one of its employees and certain blocking rights. The investor designated its employee as the director. Over the next two years, that director allegedly refused to approve transactions without the investor’s consent, blocked external financing critical to the company’s survival and requested a confidential draft contract with a competitor to share with his employer. The company ultimately ran out of funds and ceased operations. The court held that a designee who follows the investor’s instructions rather than exercising independent judgment can expose both parties to liability that contract cannot waive.

Strategic capital is not new and neither are the tensions it creates. What has changed is where the capital is going and how concentrated it has become. In the artificial intelligence space, corporate investors are active and competing aggressively: they accounted for more than half of corporate venture deals in early 2026. With the exception of a few select sectors, corporate participation has thinned rather than broadly recovered.

In sectors that attract strategic capital, companies typically have more options and greater leverage. Elsewhere, alternatives are limited, which affects the terms strategic investors are willing to offer. The governance and regulatory questions, however, arise in every sector and differ from those presented by a financial investor. A private equity fund typically focuses on maximising value; a corporate investor may share that goal while also seeking preferred access to technology or customer data or using its position to prevent the company from becoming a competitor. Differing investor motivations should inform a company’s approach to board seats and other governance rights.

Why Corporations Take Minority Stakes

Even large corporations face innovation gaps that internal research and development cannot always fill, particularly in artificial intelligence, climate technology, next-generation materials and other emerging technologies. Portfolio companies, meanwhile, increasingly seek investors that bring more than capital. Distribution partnerships, technology licenses and access to an established customer base can give a strategic investor an advantage over a financial investor.

Economic conditions also matter. Public listings remain available to a narrow set of companies and, particularly when bank lending is tight, strategic capital becomes an attractive alternative funding source without requiring the readiness a public offering demands. Corporations deploying balance-sheet capital in adjacent high-growth markets may earn better returns than repurchasing shares at elevated prices. However, because strategic capital tends to be concentrated in specific markets, many companies seeking funding may find that a strategic investor is not a viable option.

Large corporations structure minority investments according to their strategic objectives, risk tolerance and desired involvement. The simplest form is a passive financial investment, typically preferred equity with limited governance rights. More commonly, corporates seek an active minority position that pairs capital with a commercial partnership, creating incentives beyond the equity return.

The commercial partnership often drives the deal. A corporation may invest USD50 million in a growth-stage company primarily to secure a multi-year technology license, preferred supplier arrangement or right to develop products jointly. The equity aligns incentives, which can make the relationship more durable. Companies should structure the commercial and investment components with fair market value in mind so the equity price is not later characterised as compensation for something else.

Documenting the commercial rationale and arm’s-length pricing early helps avoid later valuation disputes.

For a portfolio company, strategic capital involves clear trade-offs. The commercial benefits may be immediate and substantial, but a corporate shareholder can complicate future fundraising or a sale, particularly if competitors view the relationship as exclusive. Founders should negotiate information rights, rights of first refusal and exclusivity carefully because each can restrict future flexibility.

The strongest proposals distinguish genuine commercial access from broader rights that can unnecessarily constrain the company’s future financing and partnerships.

Key things that deserve consideration are the following:

• the commercial value beyond mere capital should be defined – an acquisition or technology thesis should be tested or customer introductions, channel access, licensing or co-marketing should be secured; a minority stake should not be assumed to provide control;
• the potential for strategic investors to retreat in a downturn should be anticipated by specifying follow-on expectations, notice periods, pro rata and oversubscription rights, consequences of non-participation and protections against opportunistic early exits;
• risk that a strategic investment may foreclose competitor partnerships and signal unavailability to the broader market should be addressed by narrowly defining exclusivity terms and tailoring public messaging;
• separate but coordinated investment and commercial agreements should be used, with carefully limited cross-defaults, to preserve flexibility and support clear valuation;
• the possibility that strategic investors may prefer an acquisition over an IPO should be anticipated; expectations should be aligned through transfer rights, drag-along provisions and carefully scoped consent rights; and
• a corporate venture fund, with a defined mandate and investment process, should be distinguished from a direct balance-sheet investment, as incentives and timelines may differ.

Governance Challenges with Strategic Investors

Differing investor motivations can create tension and pose governance challenges and board representation and blocking rights only sharpen these tensions. A strategic investor with a board seat may receive competitively sensitive information about product development, customers, pricing and potential acquisitions. The director appointed by a strategic investor (often one of its employees) owes certain fiduciary duties to the company, even as the investor employs and pays them. Information barriers, recusal protocols or a more limited right to attend as a board observer rather than a full board seat can help manage the potential conflict created by the dual loyalty and motivations of the investor’s designated director.

Zync, Inc. v Porsche Investments Management, S.A., decided by the Delaware Court of Chancery in May 2026, stands out not because of the director’s alleged conduct, but because the underlying arrangement was common in the market. Despite an exculpatory clause protecting directors, the court declined to dismiss the breach-of-fiduciary-duty claims against the designee and the aiding-and-abetting claims against Porsche.

Two points are notable. First, contractual blocking rights do not by themselves insulate an investor from liability, particularly where the rights resulted from an arm’s-length negotiation. The issue was how Porsche, through its designee, exercised those rights. Second, the voting agreement attempted to eliminate liability arising from the board designation. The court found the provision too ambiguous to support dismissal and observed that, even on the investor’s reading, Delaware law does not permit a contract to eliminate liability for intentional or bad-faith conduct.

A board designee who takes instructions from the corporate investor before voting creates risk for both sides. The governance framework should anticipate divergence between the company’s interests and the investor’s commercial interests. What happens when the company wants to partner with the investor’s competitor or when the best available buyer is a competitor? These questions are far easier to answer before a transaction is pending or under negotiation.

Defining recusal and information protocols before signing is far easier than negotiating them after a competitor becomes a potential partner or buyer.

Companies should consider:

• establishing formal protocols that limit competitively sensitive information flowing to the strategic investor’s operating teams and identify who will monitor compliance;
• whether appointing an observer provides access without fiduciary duties and whether observer rights could still create information or antitrust concerns;
• defining in advance when the strategic investor’s representative must recuse, particularly for competitive transactions, related-party dealings and a sale to a competitor;
• tying board seats and enhanced governance rights to ownership thresholds in order for those rights to step down as the strategic investor’s percentage declines; and
• addressing the dual-loyalty problem expressly in the stockholders’ agreement through disclosure and recusal obligations, while recognising that exculpation will not cover intentional or bad-faith conduct.

Potential Antitrust Implications

Strategic minority investments raise antitrust questions that purely financial investments typically do not and the rules are currently in flux. The Hart-Scott-Rodino Act requires parties in certain transactions to notify the Federal Trade Commission and Department of Justice and observe a statutory waiting period before closing. For transactions closing on or after 17 February 2026, notification is generally required when the acquiring party will hold voting securities, non-corporate interests and assets post-closing valued above certain thresholds (depending on the size of the parties in some cases), which are adjusted annually. Currently, the minimum transaction threshold for filing is USD133.9 million if one party has annual sales or total assets of at least USD267.8 million and the other at least USD26.8 million in assets or revenues or USD535.5 million regardless of the parties’ size.

Meeting a threshold does not always require filing because the statute exempts acquisitions made solely for investment purposes, but courts narrowly construe that exemption. An investor who takes a board seat, negotiates consent rights over company decisions or enters a commercial relationship will often not qualify because those arrangements are inconsistent with an intention not to participate in the business. In practice, sizable strategic minority investments often require a filing.

Two developments have left this area unsettled. First, in February 2025, a substantially expanded notification form took effect, requiring more information about minority shareholders, transaction rationale and competitive overlaps. In February 2026, a federal district court in the Eastern District of Texas vacated the rule creating the expanded form and in March 2026 the Fifth Circuit declined to pause the vacatur pending appeal. The agencies are preparing new rulemaking and have accepted filings on the older form in the meantime.

The second development is more consequential for strategic investors. In March 2026, the FTC and Antitrust Division jointly requested comment on long-standing exemptions, including whether the investment-only exemption should expressly exclude an acquirer that uses its ownership to influence competitive decisions concerning price, quality or output. The agencies also asked whether the rules should capture structures that have historically fallen outside, including convertible financings, licensing arrangements and acquisitions of a company’s team rather than its business. Structures that have avoided the filing requirement may not be able to after new rulemaking.

Beyond filing requirements, the substantive analysis asks whether an investment softens competition. Partial ownership draws scrutiny because a company holding a stake in a competitor may have less reason to compete aggressively, while information rights can create a channel for coordination. Regulators do not need to find actual control: an investment well short of control can attract scrutiny, particularly where companies in the same industry hold stakes in one another. Penalties have also increased, including a USD5.6 million penalty in 2025 for exercising control before the waiting period expired and a USD12 million penalty in July 2026 for structuring a transaction to avoid filing.

Where the investor and company compete or one supplies the other, limiting governance rights to purely financial protections may reduce risk and preserve the exemption. That means no board seat, no access to competitively sensitive information and no influence over competitive strategy. It also removes much of what makes a strategic investment attractive, so the parties should address the trade-off as early as possible, ideally before signing a term sheet.

The following things should be taken into account:

• whether the investment triggers a filing under the thresholds in effect at closing, which adjust annually, should be confirmed (the current size-of-transaction threshold is USD133.9 million);
• the exemption should be treated as narrow; board seats, consent rights and commercial partnerships typically disqualify it and further limits are under consideration by the agencies;
• the investor’s and target’s relationships across product markets and geographies, including supplier and customer relationships, should be mapped before governance rights are selected;
• where overlap exists, the information that may be shared, the recipients and the methods for monitoring compliance should be specified;
• during the waiting period, the investor should not influence the target’s competitive conduct; permissible coordination should be clearly defined in light of sharply increased penalties; and
• notification requirements in multiple jurisdictions may be triggered by cross-border investments; filing obligations should be mapped early, as further discussed below.

Cross-Border Investment Screening

Foreign direct investment (FDI) screening has proliferated: more than 30 jurisdictions now operate mandatory review mechanisms, many introduced or materially expanded since 2020. Strategic investments in technology, artificial intelligence, semiconductors and critical infrastructure are frequent triggers, including where the investment is a minority position and the investor receives influence or access to sensitive information.

The EU Foreign Subsidies Regulation, in effect since mid-2023, requires notification of concentrations involving EU targets where foreign financial contributions exceed specified thresholds. This is relevant to strategic equity financing because a corporate investor’s balance-sheet capital may itself constitute a foreign financial contribution and, potentially, a foreign subsidy subject to review.

The UK National Security and Investment Act 2021 gives the UK government call-in powers over investments in 17 sensitive sectors and applies to minority stakes that confer material influence. Unlike U.S. HSR analysis, many FDI regimes operate at lower ownership thresholds, can be triggered by influence rather than control and may impose conditions (such as restricting information sharing or requiring local data storage) that directly affect the commercial partnership the investment is intended to support.

Prior to allowing any FDIs, companies should:

• map applicable mandatory and call-in regimes early by investor, target, sector and jurisdiction;
• assess whether the investor’s capital structure and foreign financial contributions meet applicable concentration thresholds before signing and filing;
• anticipate approval conditions that may restrict information sharing, governance rights or local data storage and therefore limit the commercial benefits of the investment; and
• align FDI review timelines with HSR and other closing conditions; build long-stop dates and conditions precedent around the longest review path.

Commercial Partnerships and Investment Synergies

The most successful strategic investments pair equity capital with commercial arrangements that create value independent of financial returns. These may include technology licenses, joint development, supply, distribution, data-sharing or co-marketing arrangements. Structure the commercial relationship on terms each party would accept from an unrelated counterparty, so the equity investment aligns incentives without substituting for fair pricing.

Negotiate the commercial agreement and investment documents in parallel but execute them as separate instruments. Separation preserves the ability to unwind one without necessarily unwinding the other, helps demonstrate that the equity price was not payment for commercial rights and simplifies accounting treatment.

Aligning incentives strengthens the partnership’s durability. If the investor can terminate the commercial arrangement at will while the equity is locked up, it may gain leverage to reopen commercial terms. If the arrangement extends well beyond the expected holding period, the investor loses flexibility. Aligning duration and termination provisions creates more balanced incentives.

Parties often focus on launch terms but under-negotiate termination, transition support and ownership of jointly developed IP.

Venturing into commercial partnerships requires:

• ensuring commercial terms reflect fair market value to reduce transfer-pricing challenges, related-party scrutiny and valuation distortion;
• aligning the duration and renewal provisions of the commercial agreements with the expected investment holding period;
• specifying what happens to commercial arrangements upon exit, including automatic termination, transition periods or continuation at revised terms;
• allocating ownership and post-termination rights for intellectual property created through joint development; and
• establishing mutual measures for the commercial partnership and assigning responsibility for reviewing them.

The Road Ahead

Strategic equity financing is not simply a way to fill a capital need. It has become as much a governance and regulatory exercise as a capital-raising one: the value of the investment depends on what the investor is permitted to know, influence and do after closing. The next generation of deals will be shaped less by whether a structure is technically available today than by whether it can withstand scrutiny as the commercial relationship, competitive landscape and regulatory framework evolve.

That pressure is already visible in the pending antitrust rulemaking. The FTC and DOJ are considering whether the investment-only exemption should reach or expressly exclude, convertible financings, licensing arrangements and acqui-hires, as well as investments used to influence competitive decisions. Structures designed to avoid a filing under current practice may not survive the new rules. The expanding international FDI screening landscape adds a further layer of regulatory complexity to cross-border strategic investments, often at lower ownership thresholds and with conditions that can restrict information sharing or require local data storage. At the same time, Zync’s reasoning is likely to influence stockholders’ agreements and board practice beyond the extreme facts of that case: a designee who treats the appointing investor’s instructions as a substitute for independent judgment creates exposure that drafting alone cannot eliminate.